Please select the option that best describes you:
Topics:
Hematologic Malignancies • Radiation Oncology • Pediatric Hematology/Oncology • Lymphoma • Hodgkin Lymphoma
How do you approach delivering ISRT to nodular lymphocyte predominant Hodgkin Lymphoma that has responded on FDG-PET/CT after chemotherapy?
Does the stage at diagnosis affect your decision?
Answer from: Radiation Oncologist at Community Practice
The therapeutic algorithm in stage >I lymphocyte predominant HL is extrapolated from data on classic HL. Thus, I would use the same algorithm as in HL when evaluating RT indication and dose.
Omitting radiotherapy is safe, if a favorable response has been documented on PET-CT and the patient has ...
Sign in or Register to read more